Kornimate/medical-research-clean huggingface dataset:
using artificial intelligence-platform on plaque control and periodontal treatment outcome in patients with periodontal disease-preliminary results

Conditions: Periodontal Diseases

Summary: the aim of this study was to evaluate the long-term effectiveness of an ai dental monitoring intervention on patients' periodontal disease, preventive behaviors and motivation. this randomized controlled trial included experimental group: ai group (eg-a), ai-humanized group (eg-b) and control group(cg), respectively. the eg-a and eg-b received ai dental monitoring intervention by taking mouth image at home once a week for six month. baseline and follow-up surveys were used to collect the data in periodontal index, periodontal preventive behavior and motivation.

a randomized experimental design was used. patients with periodontal disease whose aged 35-65 years were recruited through department of periodontics in kaohsiung medical university hospital. each group was expected for 100 per group, patients will be randomized into each group. g\*power (version 3.1.9.4) was used for power analysis. all patients will underwent periodontal examination at baseline and at 1-month, 3-month, 6-month follow-ups. each patients will be diagnosed periodontal disease by dentist and have more than 16 functional teeth. each patients will completed the questionnaire at baseline and at 1-month, 3-month and 6-month follow-up.

Eligibility criteria:
inclusion criteria: * age between 35-65 years old * diagnosed periodontal disease by dentist (comprehensive periodontal treatment project) * more than 16 functional teeth exclusion criteria: * have received periodontal treatment within 3 months * patient has disease related to periodontal disease (ex. drug-related excessive gum growth or blood clotting problems, pregnancy, mental illness) * disability patients

Keywords: oral hygiene artificial intelligence periodontitis periodontal diseases
effect of n-acetylcysteine on brain glutamate

Conditions: Psychosis

Summary: a double-blind, placebo controlled, crossover study to determine whether a single dose of n-acetylcysteine (a nutritional supplement) can reduce brain glutamate levels in patients with a psychotic disorder. secondary outcomes are to determine the pattern of alteration in brain perfusion and activity following a single dose of n-acetylcysteine.

this is a physiological, proof-of-concept study designed to investigate whether a single administration of n-acetylcysteine can reduce brain glutamate levels in people with psychotic disorders. previous research suggests that poor response to antipsychotics may be linked to increased levels of glutamate in the brain (egerton et al., 2012; demjaha, egerton et al., 2013). reducing brain glutamate levels may therefore be therapeutic. this study tests whether it is possible to reduce brain glutamate levels in psychotic disorders. this is a small pilot study to determine whether a single administration of nac can reduce brain glutamate levels in psychosis. at the same time, we will also examine the effects of nac on brain resting perfusion and activity, to gain more information about how nac may be acting. this study will recruit participants with a previous diagnosis of a psychotic disorder. there will be three study visits, 1-2 weeks apart. the first visit will involve a physical health check, blood sample and an interview to assess current symptoms and confirm medical history. on the second and third visits participants will have an mri scan, lasting one hour, after taking capsules containing either 2400mg nac or placebo.

Eligibility criteria:
inclusion criteria: * over 18 years of age * diagnosis of a psychotic disorder * have mental capacity to consent exclusion criteria: * diagnosed drug or alcohol dependency, with the exception of nicotine * pregnancy, as determined through a urine pregnancy test * presence of any physical health abnormality which may impact on safety to participate in the research, as determined by a study clinician on the basis of the physical health check and the available medical information. * presence of electronic or metallic implants contraindicated to mri scanning at 3 tesla, or presence of any other contraindication to mri * history of asthma * history of epilepsy or any other seizure * under 18 years of age * lacking mental capacity to consent * current or previous use of nac * currently prescribed clozapine
the role of lung and diaphragm ultrasonography in predicting clinical progression in hypoxemic respiratory failure

Conditions: Diaphragm Ultrasonography; Lung Ultrasound; Hypoxemic Respiratory Failure

Summary: the goal of this observational study is to evaluate whether the risk of intubation in patients with hypoxemic respiratory failure who were monitored in the intensive care unit and received non-invasive mechanical ventilation and high-flow nasal oxygen treatment could be predicted using lung and diaphragm ultrasound. the main question it aims to answer is: can lung and diaphragm ultrasound predict the risk of intubation in patients with hypoxemic respiratory failure?

between january 1, 2024, and may 1, 2024, the diaphragm thickness fraction, excursion, lus score, rox index, and the luss/rox index ratio were evaluated using lung and diaphragm ultrasound in 91 patients admitted to the intensive care unit with a diagnosis of hypoxemic respiratory failure. these evaluations were performed at the 6th, 12th, 24th, and 48th hours of their icu stay, and during intubation if the decision for intubation was made

Eligibility criteria:
inclusion criteria: -pao2 \<60 mmhg detected in arterial blood gas samples at the time of admission to the intensive care unit exclusion criteria: * under the age of 18 * history of lung and diaphragm surgery * congenital, acquired or traumatic diaphragmatic hernia * diaphragm paralysis * hemodynamic instability requiring vasoactive drug support * do not agree to participate in the study
evaluation of an adaptative, multidisciplinary, reach-out program, facilitating pre exposition hiv prophylaxis (prep) prescription and retention in care, in a group of trans womens (tw) at high risk of hiv infection.

Conditions: Transgenderism

Summary: evaluation of an adaptative, multidisciplinary, reach-out program, facilitating pre exposition hiv prophylaxis (prep) prescription and retention in care, in a group of trans womens (tw) at high risk of hiv infection.


Eligibility criteria:
inclusion criteria: * trans woman ≥ 18 years old; negative hiv-1 and hiv-2 serology; participant on prep or request to start prep or reporting present, past or future exposure to hiv; participant agreed with the constraints imposed by the study (every 3 months visits); non opposition. exclusion criteria: * subject with positive hiv serology; subject with clinical signs suggesting a primary hiv infection; subjects planning to travel/live abroad for more than 3 consecutive months or planning to live outside ile-de-france region; creatinine clearance \< 60 ml/min (cockroft's formula); history of chronic kidney disease, osteoporosis, osteopenia; subject receiving a potentially nephrotoxic treatment (long-term nonsteroidal anti-inflammatory drugs); ongoing post-exposure antiretroviral therapy (the participant may be tested 6 weeks after the end of treatment); treatment under investigation; chronic gastrointestinal illness (or chronic nausea or vomiting) interfering with intestinal absorption; hbs antigen positive or with an isolated anti-hbc antibody if participant is not ready to take continuous prep; life-threatening illness (cancer) or other serious illness (cardiovascular, renal, pulmonary, unstable diabetes) which would require treatment that could interfere with treatment adherence; hypersensitivity to one of the components of tdf / ftc.
eeg encephalopathy patterns in immune effectors cells-associated neurotoxicity syndrome (icans)lay language

Conditions: Immune Effector Cell Encephalopathy; Neurotoxicity

Summary: immune effectors cells-associated neurotoxicity syndrome (icans) is one of the most clearly defined acute toxicities after car-t cells infusion. the investigators conducted a prospective cohort study of all patients who received car t cell infusions on the hematology department from montpellier university medical center. each patient was assessed between the 6th and 8th day after infusion by a neurological clinical examination, an electroencephalogram, and a brain mri. the aim of the studies is to describe the eeg pattern associated with icans.

the investigators will conduct a prospective cohort study of all patients who received car t cell infusions in the hematology department from montpellier university medical center. to be eligible for enrollment, patients should have to be 18 years of age or older. all the patients will have histologically confirmed: diffuse large b-cell lymphoma, b-cell acute lymphoblastic leukemia, follicular lymphoma, or mantle cell lymphoma. each patient will have a pet ct before infusion to determine metabolic response status according to the lugano grading classification. all patients will have preconditioning brain imaging by mri. each patient will be assessed between the 6th and 8th day after infusion by a neurological clinical examination, an electroencephalogram, and a brain mri. patients will be called back one month later to report any new neurological event and an eeg was performed if abnormalities were found on the first. all neurological symptoms documented in daily progress notes will be catalogued. the investigators will use astct icans consensus grading for adults to evaluate neurotoxicity.

Eligibility criteria:
inclusion criteria: * histologically confirmed: diffuse large b-cell lymphoma, b-cell acute lymphoblastic leukemia, follicular lymphoma, or mantle cell lymphoma. * with infusion of car t-cells exclusion criteria: - age \< 18 years
a study to evaluate the pharmacokinetics and safety of asc16 tablets in healthy volunteers in china

Conditions: Chronic Hepatitis c

Summary: the purpose of this study is to evaluate the pharmacokinetics and safety of asc16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.


Eligibility criteria:
inclusion criteria: * age between 18-45 years old; * male body weight not less than 50kg; female body weight not less than 45kg; bmi in the range of 19\~24kg/m2 * healthy men or women based on history, physical examination, laboratory examination and ecg. * no plan of pregnancy in at least six months, and willing to take effective measures to prevent contraception from the first time when the drug is administered till the last time the drug is administered within 30 days. * female has negative pregnancy tests at the screening stage. * voluntary to sign the informed consent. exclusion criteria: * have medical history, or has disease, such as cardiovascular system, respiratory system, endocrine and metabolic system, urinary system, digestive system, blood system, nerve system disease or psychiatric disease and acute or chronic infectious diseases and malignant tumors. * has a history of drug or food allergy. * positive hepatitis a antibody，positive hepatitis b surface antigen， positive hepatitis c antibody，syphilis antibody or hiv antibody at screening. * laboratory tests out of normal range and judged by the investigators as clinically significant. * had gastrointestinal surgery, vagotomy, intestinal resection or any possible interference with gastrointestinal peristalsis, ph or absorbed by surgery. * pregnant, lactating women and people who unwilling to take effective measures to prevent contraception. * people who consumed pomelo, apple or orange and foods or drinks containing their extracted ingredients within 3 days of taking the drug. * any prescription or over-the-counter medications, herbs, and vitamins are required to be taken prior to or within the first month of taking the drug. * selected within the first 6 months of smoking, alcohol, drug abuse or history of drug abuse. * selected within the first 3 months had blood loss or blood donation of 200ml. * participate in other clinical trials within the first 3 months of the study and received other study drug treatment. * in addition to the above, the investigators judged not suitable for participating in this clinical trial.
relation between the value of platelet clot stiffness (pcs) obtained by sonorheometric method of delocalized hemostasis (quantra®), and the presence of a disorder of primary hemostasis, in cardiac surgery patients. plaqua-study

Conditions: Primary Haemostasis Disorder in Cardiac Surgery Patients

Summary: the goal of this study is to determine whether the platelet clot stiffness (pcs) measured by quantra® is predictive of an abnormality in primary haemostasis intraoperatively in cardiac surgery performed under extracorporeal circulation. the aim is to compare the assessment of platelet function by quantra® (data called pcs, obtained in around ten minutes) with laboratory tests which are validated, but which cannot be used in current practice (response time too long, in particular). we are therefore seeking to determine whether quantra is reliable in the search for a primary hemostasis anomaly, defined by significant thrombocytopenia (platelet count below 100g/l), and/or a prolongation of platelet occlusion time measured by pfa-200® (normal or increased). this clinical research project will last 12 months. it will take place in the cardiac surgery operating room at chu félix guyon, and will involve 100 patients. patients who have consented to participate in this research project will be managed in the operating room in the usual way, with no change to their usual care (in terms of treatments received). at the end of the surgery, we will add 3 blood samples (maximum 8.1ml) for analysis to assess platelet function and compare with quantra data. this blood sample will be the only procedure performed. medical management remains standard and will not be disrupted by this test.


Eligibility criteria:
inclusion criteria: patients * hospitalized for scheduled cardiac surgery performed under extracorporeal circulation, including coronary bypass, valve replacement, aortic arch and combined surgeries. exclusion criteria: patients: * with preoperative hematocrit \< 35% and preoperative platelet count \< 80,000 g/l (validity of pfa-200® test) * with known congenital or acquired willebrand's disease, or known platelet dysfunction. * on double antiaggregation, not discontinued at the time of surgery * vulnerable patients: minors or protected adults, pregnant women, patients not affiliated to the social security system. * emergency situation

Keywords: primary haemostasis disorder platelet clot stiffness quantra von willebrand factor deficiency
use of homeopathy in patients suffering from long covid-19

Conditions: Adjustment Reaction With Physical Symptoms

Summary: in some patients, coronavirus (covid-19) can cause symptoms that last weeks or even months after the infection has gone. the aim of this study was to describe the effect of adjunctive individualized homeopathic treatment delivered to long-covid-19 patients with previously confirmed symptomatic sars-cov-2 infection.

all patients had been tested positive for sars-cov-2 before having developed long-covid-19 symptoms. several testing methods were carried out in each patient to analyze a sars-cov-2 infection. for a confirmed infection, at least 3 out of these 5 tests had to be positive. tests for the orthomyxoviruses influenza a and b, human metapneumovirus (hmpv) and paramyxoviruses were negative unless stated otherwise. the homeopathic physician treated all long-covid-19 patients by individualized homeopathy. repertorization of the symptoms of the current pandemic and a search in the current homeopathic literature on covid-19 was performed using computer program. all available homeopathic medicinal products (hmps) could be chosen by the treating physician. modified monarch criteria were assessed post hoc by all authors. deviations were solved by discussion in person. clinical outcome of case reports was evaluated using the "modified naranjo criteria for homeopathy-causal attribution inventory". eight points is assumed as the limit for potential correlation between homeopathic therapy and amelioration of the symptoms or healing in chronic cases.

Eligibility criteria:
inclusion criteria: long covid-19 symptoms following recovery from sars-cov-2 infection exclusion criteria: patients not signing informed consent

Keywords: complementary therapy homeopathy covid-19 long-covid-19 sars-cov-2
recombinant human fibroblast growth factor-2 (rhfgf-2) in gingival recession defects

Conditions: Periodontitis

Summary: this study was a single-arm trial to obtain preliminary data on the efficacy of collagen membranes impregnated with recombinant human fibroblast growth factor (rhfgf-2) in the treatment of miller's class i and class ii gingival recessions.

soft tissues can be regenerated to cover root exposure and a thin biotype can be converted into a thick biotype by using recombinant human growth factor technology. a recent review stated that growth factors could enhance soft tissue regeneration which includes restoration of mucogingival architecture and regeneration of periodontal hard and soft tissues including bone, cementum and periodontal ligament fibers. fibroblast growth factor-2 (fgf-2), a heparin-binding cytokine with strong angiogenic activity stimulates the proliferation of undifferentiated mesenchymal cells. these functions can be applied in mucogingival surgery as fgf-2 promotes bone and cementum formation and exhibits an increased potential to promote periodontal regeneration in recession defects.

Eligibility criteria:
inclusion criteria: * systemically healthy subjects between 20-55 years presenting with miller's class i or class ii gingival recession\[ exclusion criteria: * 1. recessions associated with root demineralization/caries, deep cervical abrasion or pulpal pathology, 2. patients with history of systemic conditions affecting periodontium and, 3. smokers.

Keywords: gingival recession fibroblast growth factor 2 periodontal atrophy
acupuncture for impaired glucose tolerance in overweight/obese population

Conditions: Impaired Glucose Tolerance; Overweight; Obese; Prediabetic State

Summary: this is a prospective, multicenter, parallel-group, participants- and assessors-blinded randomized trial aiming to evaluate the effectiveness and safety of acupuncture in improving glucose metabolism for overweight/obese participants with igt, in comparison with sham acupuncture.

the trial will be conducted at three hospitals in china. 196 eligible subjects will be randomly assigned (1:1) to the acupuncture or sham acupuncture group to receive either 30-session acupuncture/sham acupuncture treatment over 12 weeks based on lifestyle intervention and 24-week follow-up. the primary outcome is the change in the value of 2-hour blood glucose (2hpg) from baseline at the end of the 12-week treatment. additionally, compliance, blinding, and safety will also be assessed. all statistical tests will be performed using a two-sided test, a p-value of less than 0.05 is considered significant.

Eligibility criteria:
inclusion criteria: 1. those who meet the diagnostic criteria of overweight/obesity and igt: ①igt: fasting blood glucose (pg) is lower than 7.0mmol/l, and 2-hour blood glucose (2hpg) after oral 75g glucose tolerance test (ogtt) is between 7.8\~11.1mmol/l. ②overweight: 24.0 \< bmi ≤ 27.9, obesity: bmi ≥ 28.0, or bmi ≤24.0 but waist circumference ≥85 cm (male) /≥80 cm(female). 2. 18-60 years old; 3. those who can appropriately describe their wishes, voluntarily fill in the informed consent form and agree to participate in clinical trials. exclusion criteria: 1. obesity secondary to heredity, drugs, and diseases; 2. those who have received weight-loss treatment including acupuncture and drugs in the past 3 months; 3. those who have taken drugs that have known effects on body weight or appetite in the past 3 months, such as corticosteroids, antidepressants, non-selective antihistamines in vivo, nicotine substitutes, etc; 4. igt is caused by abnormal thyroid function, endocrine tumors, extensive liver damage; 5. abnormal glucose tolerance caused by thiazide diuretics, β-blockers, nicotinic acid drugs, quinolones, calcineurin inhibitors, interferon-alpha, etc; 6. received antidiabetic medicines in the past 3 months； 7. participants with serious primary diseases such as heart, lung, brain, liver, or hematopoietic system diseases, progressive malignant tumor, or other serious consumptive diseases; 8. participants with cognitive impairment and severe mental illness; 9. participants with blood coagulation dysfunction, and scare of needles； 10. pregnant, breastfeeding, or planning to conceive within 37 weeks.

Keywords: impaired glucose tolerance overweight obese prediabetic state acupuncture randomized controlled trial
raynaud's treatment study (rts)

Conditions: Cardiovascular Diseases; Heart Diseases; Raynaud's Disease; Vascular Diseases

Summary: to determine the relative efficacy of usual medical care and a course of treatment by thermal biofeedback in reducing vasospastic attacks characteristic of raynaud's syndrome. also, to confirm the frequency and severity of attacks, examine the role of psychophysiological factors in precipitating attacks, and assess the influence of treatment on health quality of life.

background: primary raynaud's phenomenon is a peripheral vascular disorder resulting in vasospastic attacks provoked by cold and/or emotional stress. attacks most often occur in the fingers, but may occur in other extremities as well. design narrative: randomized. patients were assigned to one of four treatment groups: slow release nifedipine, a calcium channel blocker; pill placebo; temperature biofeedback; or electromyograph biofeedback from the frontalis muscle. the primary endpoint was reduction in number of vasospastic attacks. other endpoints included: other measures of raynaud's attacks including frequency, severity, duration, response to laboratory-based cold challenge, and quality of life.

Eligibility criteria:
men and women with documented primary or secondary raynaud's syndrome.